Cargando…

The JAK inhibitor tofacitinib ameliorates immune-mediated liver injury in mice

The prevalence of immune-mediated liver diseases such as autoimmune liver disease or viral hepatitis has increased in recent years, and the side effects of pre-existing treatments are a worldwide problem. Regulatory T cells (Tregs) and T helper 17 (Th17) cells play important roles in the development...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Han, Feng, Xinxia, Han, Ping, Lei, Yu, Xia, Yujia, Tian, Dean, Yan, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854585/ https://www.ncbi.nlm.nih.gov/pubmed/31638166 http://dx.doi.org/10.3892/mmr.2019.10750

Ejemplares similares

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

Effect of the JAK/STAT Inhibitor Tofacitinib on Macrophage Cholesterol Metabolism
por: Adorni, Maria Pia, et al.
Publicado: (2023)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2013)

Tofacitinib Ameliorates Lipopolysaccharide-Induced Acute Kidney Injury by Blocking the JAK-STAT1/STAT3 Signaling Pathway
por: Yun, Yang, et al.
Publicado: (2021)

Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib
por: Yang, Qiao, et al.
Publicado: (2018)

Effects of Hyperlipidemia on the Pharmacokinetics of Tofacitinib, a JAK 1/3 Inhibitor, in Rats
por: Won, Jong Mun, et al.
Publicado: (2023)

Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
por: Sardana, Kabir, et al.
Publicado: (2023)

Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis
por: Bezzio, Cristina, et al.
Publicado: (2023)

Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series
por: Xu, Qingqing, et al.
Publicado: (2023)

Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis
por: Morelli, Martina, et al.
Publicado: (2018)

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going
por: Liu, Eleanor, et al.
Publicado: (2022)

Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib
por: Okiyama, Naoko, et al.
Publicado: (2014)

Tofacitinib Promotes Functional Recovery after Spinal Cord Injury by Regulating Microglial Polarization via JAK/STAT Signaling Pathway
por: Ma, Hongdao, et al.
Publicado: (2023)

Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis
por: Kaine, Jeffrey, et al.
Publicado: (2020)

Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib
por: Chimenti, Maria Sole, et al.
Publicado: (2021)

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
por: Shide, K, et al.
Publicado: (2017)

Tofacitinib fails to prevent T cell transfer colitis in mice but ameliorates disease activity
por: Subramanyam, Sudheendra Hebbar, et al.
Publicado: (2023)

Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
por: Di Benedetto, Paola, et al.
Publicado: (2021)

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

Drug-induced liver injury due to tofacitinib: a case report
por: Mardani, Masoud, et al.
Publicado: (2023)

Amelioration of unstable vitiligo and normalization of thryroglobulin antibodies with oral tofacitinib
por: Moore, Angela Yen, et al.
Publicado: (2022)

JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation
por: Ikeda, Keigo, et al.
Publicado: (2017)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
por: Traves, Paqui G, et al.
Publicado: (2021)

Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib
por: Jiang, Zong, et al.
Publicado: (2023)

Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice
por: Sendo, Sho, et al.
Publicado: (2019)

Tofacitinib protects intestinal epithelial cells against oxygen-glucose deprivation/reoxygenation injury by inhibiting the JAK/STAT3 signaling pathway
por: Yang, Jing, et al.
Publicado: (2021)

The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice
por: Shaker, Mohamed E., et al.
Publicado: (2022)

Sa127 AN IBD-RISK VARIANT IN PTPN2 PROMOTES CELLULAR UPTAKE OF SARS-COV-2, WHICH IS MITIGATED BY THE JAK INHIBITOR TOFACITINIB
por: Spalinger, Marianne, et al.
Publicado: (2021)

Treatment of STING-associated vasculopathy with onset in infancy in patients carrying a novel mutation in the TMEM173 gene with the JAK3-inhibitor tofacitinib
por: Tokgun, Pervin Elvan, et al.
Publicado: (2023)

Tofacitinib
Publicado: (2012)

Tofacitinib reduces acute lung injury and improves survival in a rat model of sepsis by inhibiting the JAK-STAT/NF-κB pathway
por: Zhang, Xinxin, et al.
Publicado: (2023)

Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
por: Yanaba, Koichi, et al.
Publicado: (2012)

Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib
por: Sweep, Mark W. D., et al.
Publicado: (2023)

Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice
por: Llop-Guevara, Alba, et al.
Publicado: (2015)

Tofacitinib Ameliorates Lupus Through Suppression of T Cell Activation Mediated by TGF-Beta Type I Receptor
por: Yan, Qing, et al.
Publicado: (2021)

Saffron reduces the liver fibrosis in mice by inhibiting the JAK/STAT3 pathway
por: Huang, Lijuan, et al.
Publicado: (2023)

Daphnetin ameliorates acute lung injury in mice with severe acute pancreatitis by inhibiting the JAK2–STAT3 pathway
por: Yang, Shujun, et al.
Publicado: (2021)

TNF-α inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice
por: Gao, Jian, et al.
Publicado: (2022)

Erratum to Tofacitinib
Publicado: (2012)

Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib
por: Xing, Qian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9f4ok8e5st0up2upk8fn9ujuvq